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Non-small-cell lung cancer (NSCLC), which accounts for 81% of
lung cancers (478 000 new cases per year), is the leading cause of
death from malignant disease in men in Western countries (28% of
all cancer deaths) (Parkin and Saxo, 1993). Pulmonary resection
provides high chance for cure in NSCLC patients with early-stage
disease, but the majority of patients (70%) have either locally
advanced lesions or disseminated disease at diagnosis.
Locally advanced NSCLC is a heterogeneous disease with a
5-year survival ranging from 40% for T3N0–1 disease to 10–30%
and less than 10% for N2 and stage IIIB disease respectively.
Selected patients with minimal N2 involvement (not clinically
apparent mediastinal disease) are considered as candidates for
surgery with a 5-year survival rate of 10–20%. However, the
majority of patients in stage IIIA presents with clinical N2
disease, which is considered by most surgeons to be inoperable,
with few 5-year survivors after surgical resection alone (Ginsberg
et al, 1997).
In patients with stage IIIB disease, surgical treatment is not
feasible due to the extent of local tumour spread and chest irradia-
tion is considered the standard treatment. However, the median
survival of patients treated with radiotherapy alone is only approx-
imately 10 months with a 5-year survival of less than 10%, due to
a high rate of both local failure (40–60%) and distant metastases
(35–50%) (Choi, 1983; Perez, et al, 1987).
Meta-analysis results (Non-small Cell Lung Cancer
Collaborative Group, 1995) demonstrate a survival benefit with
the use of platinum-based chemotherapy in both locally advanced
(13% reduction in the risk of death as compared to radical radio-
therapy alone) and metastatic disease (27% reduction in the risk of
death as compared to best supportive care).
The early use of chemotherapy in the treatment of locally
advanced NSCLC might offer the opportunity to treat widespread
sub-clinical disease and might enable the resection of some
inoperable lesions. In addition, response rate in locally advanced
disease is much higher than that achievable in metastatic setting,
ranging from 40% to 60%, and combined modality therapy (i.e. a
local treatment modality plus an effective systemic therapy) has
been demonstrated to improve survival in selected stage III
patients (Roth et al, 1994; Bonomi and Penfield, 1997; Rosell et al,
1994). Combination chemotherapy has shown superior activity as
compared to single-agents and platinum-based regimens are
considered the treatment of choice (Ginsberg et al, 1997).
Among the most active drugs in NSCLC, ifosfamide, as single
agent, produces an objective response rate of approximately 25%
in metastatic disease and the use of the uroprotective agent mesna
permits its safe use in combination with cisplatin (Eberhardt and
Niederle, 1992).
In the present study, we have explored the toxicity and activity
of a combination regimen including ifosfamide, cisplatin and
etoposide (ICE) as initial treatment for locally advanced inoper-
able NSCLC. Based on previous experiences with the ICE
regimen, which had shown myelosuppression to be a significant
dose-limiting toxicity (Ardizzoni et al, 1987; Paccagnella et al,
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Fischer et al, 1994; Perez et al, 1994), the treatment was adminis-
tered with granulocyte colony-stimulating factor (G-CSF) support.
PATIENTS AND METHODS
Eligibility and treatment evaluation
Between March 1993 and February 1997, 44 patients with histo-
logically or cytologically confirmed stage III (according to the
tumour-node-metastasis (TNM) classification (American Joint
Committee, 1992) NSCLC were entered in this phase II study.
Eligibility criteria included: radically unresectable disease (as
evaluated by the thoracic surgeon, stages IIIA and IIIB), presence
of bidimensionally measurable lesions, performance status (WHO)
of 0–2, absolute neutrophil count (ANC) above 1.5 ´ 109 l–1, platelet
count above 100.0 ´ 109 l–1, adequate renal (creatinine clearance ³
60 ml min–1) and hepatic function.
Exclusion criteria included: pregnant or lactating women, or
women of childbearing potential not using adequate contraception;
previous treatments for NSCLC; concomitant serious medical
illnesses.
Pretreatment evaluation included: physical examination,
complete blood count, platelet count, serum chemistries, creati-
nine clearance, electrocardiogram (ECG), chest X-ray, computer-
ized tomography (CT) scan of the brain, chest and upper abdomen,
and radionuclide bone scan. Whenever the N status was unclear, as
evaluated by clinical/radiological studies, mediastinoscopy was
performed to better define the stage. Weekly complete blood count
and platelet count, serum chemistries, physical examination and
chest X-ray were performed before each course of treatment. In
the first ten patients, complete blood count and platelet count were
performed every other day to better define haematological toxicity.
Toxicity was graded according to the standard WHO (Miller et al,
1981) criteria.
Response to treatment was assessed by CT scan after three
courses and defined according to the standard WHO criteria.
Imaging studies were thoroughly examined by a team of indepen-
dent reviewers composed by a radiologist, a thoracic surgeon and a
medical oncologist.
The study protocol was approved by the institutional Ethical
Committee and all patients gave their informed consent.
Treatment plan
Combination chemotherapy was administered, in out-patient
setting, every 3 weeks as follows: ifosfamide 1.5 g m–2 day–1 as
30 min intravenous (i.v.) infusion on days 1–3, cisplatin 25 mg m–2
day–1 as i.v. infusion following adequate hydration with at least
2 l normal saline on days 1–3, and etoposide 100 mg m–2 day–1 as
30 min i.v. infusion on days 1–3. The uroprotector mesna at the
dose of 1.5 g m–2 day–1 as i.v. bolus, in two divided doses, was
routinely administered.
Prophylactic r-metHuG-CSF was given at the dose of 5 mg kg–1
day–1 subcutaneously (s.c.) from day 4 to day 14 in the first ten
patients. Based on the results of the haematological toxicity
analysis performed in these patients, G-CSF was then routinely
administered at the dose of 5 mg kg–1 every other day from day 4 to
day 14.
A 25% dose reduction was planned in the event of grade 4
myelosuppression. The courses were repeated every 3 weeks,
provided that the patients had totally recovered from toxicity
(ANC above 1.5 ´ 109 l–1, platelet count above 100.0 ´ 109l–1, any
non-haematological toxicity grade ≤1), with a maximum accept-
able delay of 2 weeks.
Ondansetron (8 mg i.v.) and dexamethasone (20 mg i.v.) were
routinely given 30 min before cisplatin administration, as anti-
emetic medication.
Statistical analysis
Time to progression (TTP) was calculated from the first day of
treatment to the time of progression. Overall survival (OS) was
calculated from the on-study day to the date of death or last
follow-up. Continuous data were summarized as the median and
range, and 95% confidence intervals (CI) were calculated where
indicated. Response duration and survival curves were calculated
according to the Kaplan–Meier method (Kaplan and Meier, 1958).
RESULTS
Patient characteristics and response to treatment
From March 1993 to February 1997, 44 patients entered the study.
Forty-three patients were eligible, one patient who had a diagnosis
of small-cell lung cancer at surgery was considered not eligible.
Patient characteristics are described in Table 1.
Thirty-eight patients received at least three cycles of the
planned treatment; two patients received only two courses, due to
early disease progression (one patient) and to treatment-unrelated
death (one patient died of acute myocardial infarction); three
patients received only one cycle of chemotherapy, due to early
progression.
Forty-two patients were evaluable for response and one patient
could not be evaluated because of treatment-unrelated death after
the second cycle. The overall response rate (ORR) for the whole
group was 69% (95% CI 55–83%), 90% (95% CI 71–100%) for
patients with stage IIIA, and 62% (95% CI 45–79%) for patients
with stage IIIB respectively (Table 2).
Ten patients (8/10 IIIA, 2/33 IIIB) underwent radical surgery
after three courses of chemotherapy, with two patients receiving
two additional cycles of chemotherapy and radiotherapy (60 Gy)
before the surgical treatment respectively.
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Table 1 Patient characteristics
Entered 44
Eligible 43
Median age (range) 58 (38–76)
Sex
Male 36
Female 7
Median WHO PS (range) 0 (0–2)
02 3
11 8
22
Stage
IIIA 10
IIIB 33
Histology
Squamous 28
Adenocarcinoma 10
Other 5According to protocol design, 17 patients not amenable to
surgery underwent radiotherapy with curative intent. Among
these, three patients achieved further reduction in tumour size with
respect to post-chemotherapy evaluation, two had stable disease
(SD), eight had progressive disease (PD) and four were not evalu-
able (NE). Based on the preliminary safety data with the study
regimen, a protocol amendment was subsequently introduced,
allowing for the administration of further chemotherapy up to a
maximum of six cycles. Four patients received one to three addi-
tional courses (one achieved further reduction in tumour size, two
had SD and one had PD) and two patients received two or three
additional cycles of chemotherapy followed by radiotherapy (one
SD, one NE).
Median TTP for patients not undergoing surgery (n = 33) was 8
months (range 3–34+). Median disease-free survival for patients
rendered NE by surgery (n = 10) was 26 months (range 1–54+).
Median OS for the entire group was 12.5 months (range 2–57+)
(Figure 2); median OS for resected and non-resected patients was
31 months (range 3–57+) and 10 months (range 2–36+), respec-
tively (data not shown).
Haematological toxicity
Thirty-nine patients and 114 cycles were evaluable for haemato-
logical toxicity. Four patients were not evaluable, due to the lack
of complete haematological data. Myelosuppression was the main
toxicity observed with grade 3–4 neutropenia occurring in 41% of
the patients and in 21% of the cycles respectively. Neutropenic
fever was observed in 15% of the patients and in 5% of the courses
without life-threatening infections. Grade 3–4 thrombocytopenia
occurred in 10% of the patients and in 13% of the cycles with no
episodes of bleeding. Grade 3 anaemia was observed in 10% of the
patients and 3% of the courses (Table 3). One-week treatment
delay was necessary in only 4/101 courses and ifosfamide dose
was reduced by 25% in 3/39 patients and by 50% in only two
patients, due to haematological toxicity. Median delivered dose-
intensity (DI) for each drug was: ifosfamide 1.5 g m–2 week–1
(100% of the planned DI, range 0.75–1.5), cisplatin 25 mg m–2
week–1 (100% of the planned DI, range 18.75–25), and etoposide
100 mg m–2 week–1 (100% of the planned DI, range 75–100).
G-CSF was administered daily in the first ten patients (Figure
1A). Median neutrophil nadir was 1.350 ´ 109 l–1 (range 16–8874)
and occurred between days 10 and 12. Based on our previous
ICE combination in locally advanced NSCLC 1033
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Table 2 Response to chemotherapy
Patient population Response rate (95% CI)
Evaluable (n = 42) 69% (55–83)
CR: 1
PR: 28
SD: 7
PD: 6
Stage IIIA (n = 10) 90% (71–100)
PR: 9
SD: 1
Stage IIIB (n = 32) 62% (45–79)
CR: 1
PR: 19
SD: 6
PD: 6
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Figure 1 ANC profile in patients receiving G-CSF supported ICE regimen. The first ten patients received prophylactic G-CSF continuously from day 4 to day
14 (A). Subsequent patients (n = 29) received G-CSF on an every other day schedule (B). Median ANC profile during the first three courses is shownexperience with different G-CSF schedules to support adjuvant
chemotherapy for breast cancer (Calabresi et al, 1995), G-CSF
was administered according to an every other day schedule in
subsequent patients in order to avoid leucocytosis and due to phar-
maco-economic reasons (Figure 1B). Median neutrophil nadir in
the latter group was 1.056 ´ 109 l–1 (range 87–6315). No differ-
ences in haematological toxicity were observed among patients
treated with daily G-CSF as compared to patients treated with G-
CSF administered on every other day.
Non-haematological toxicity
Alopecia was ubiquitary. A reversible drop in creatinine clearance
below 60 ml min–1 was observed in only two out of 39 evaluable
patients, in the absence of clinical signs and symptoms of renal
insufficiency. Both patients had a 1-week treatment delay and one
of them also had a 50% cisplatin dose reduction in subsequent
cycles. Gastrointestinal toxicity was mild, with grade 3 nausea and
vomiting in 13%, grade 1–2 mucositis in 20% and grade 1–2
constipation in 13% of the patients respectively. Eight patients
(20%) experienced a mild neurosensorial toxicity. A grade 1–2
increase in liver enzymes was observed in 20% of the patients
(Table 4).
DISCUSSION
This phase II study shows that the ICE combination is an effective
regimen in inoperable stage III NSCLC, with an overall response
rate of 69% (95% CI 55–83%) and a median overall survival of
12.5 months (range 2–57+). In addition, an impressive resection
rate of 80% was observed in the ten patients with stage IIIA
disease. Neutropenia was the main toxicity, never leading to life-
threatening episodes.
In locally advanced disease first-line chemotherapy achieves a
high response rate (range 35–70%), with platinum-containing
regimens being considered the treatment of choice. Among the
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Figure 2 Overall survival. Kaplan–Meier estimation of cumulative probability of survival. Median OS: 12.5 months (range 2–57+)
Table 3 Haematological toxicity (WHO)
Per patient (n = 39) Per cycle (n = 114)
Toxicity G1 G2 G3 (%) G4 (%) G1 G2 G3 (%) G4 (%)
Leucopenia 5 4 12 (31) 5 (13) 14 12 15 (13) 7 (6)
Neutropenia 2 3 9 (23) 7 (18) 6 9 14 (12) 10 (9)
Neutropenic fever 2 4 – – 2 4 – –
Anaemia 10 15 4 (10) – 34 22 4 (3) –
Thrombocytopenia 7 6 9 (23) 1 (3) 17 13 14 (12) 1 (1)several drugs used in association with CDDP, vinca alcaloids and
epipodophyllotoxins have proven the most effective (Martini et al,
1993; Bonomi and Penfield, 1997; Elias et al, 1997; Rosell et al,
1997). In spite of a higher toxicity, three-drug combinations seem
to be superior in terms of activity and further investigations of new
active regimens, with acceptable toxicity, are still needed.
In the last decade, ifosfamide-containing regimens have been
investigated by several authors yielding overall response rates
ranging from 40% to 70% (Eberhardt and Niederle, 1992) in
advanced NSCLC, although significant toxicity, including renal
insufficiency, has been reported. In earlier reports of
ifosfamide/cisplatin/etoposide regimens, a substantial activity was
documented in both locally advanced and metastatic disease.
However, severe myelosuppression was the most common dose-
limiting toxicity precluding the delivery of the planned DI in a
high percentage of patients. In the study by Ardizzoni et al (1987)
the projected DI of 1.5 g m–2 week–1, 30 mg m–2 week–1, and
60 mg m–2 week–1 for ifosfamide, cisplatin and etoposide respec-
tively, could not be delivered due to excessive myelotoxicity (two
septic deaths and four cases of grade 4 leukopenia out of 13
patients), leading to a reduction in the cisplatin dose to 15 mg m–2
week–1. In their randomized phase II study, Paccagnella et al
(1990) treated 38 patients with ifosfamide (planned DI 1.7 g m–2
week–1), cisplatin (planned DI 27 mg m–2 week–1) and etoposide
(planned DI 80 mg m–2 week–1); treatment delays were necessary
in 47% of patients, with ten episodes of leukopenia-induced infec-
tion and one septic death. In the study by Pujol et al (1990) in 33
patients treated with ifosfamide (planned DI 2 g m–2 week–1),
cisplatin (planned DI 33 mg m–2 week–1) and etoposide (planned
DI 133 mg m–2 week–1) severe neutropenia was observed in 77% of
patients and severe thrombocytopenia in 62%, with one toxic
death. Shepherd et al (1992) reported a median neutrophil count at
nadir of 0.275 ´ 109 l–1, with 14 episodes of neutropenic fever and
two toxic deaths in 47 patients who received a planned DI of 1 g
m–2 week–1 of ifosfamide, 19 mg m–2 week–1 of cisplatin and 75 mg
m–2 week–1 of etoposide. Shirinian et al (1992) reported a 90%
incidence of severe neutropenia in 20 patients treated with
ifosfamide 1.8 mg m–2 day–1 (days 1–3), cisplatin 20 mg m–2 day–1
(days 1–3) and etoposide 80 mg m–2 day–1 (days 1–3) every 3–4
weeks, and a 52% incidence of severe neutropenia in 19 patients
treated at lower starting doses (ifosfamide 1.5 mg m–2 day–1, days
1–3; cisplatin 17 mg m–2 day–1, days 1–3; etoposide 65 mg m–2
day–1, days 1–3), with febrile neutropenia with or without docu-
mented infection in four patients and one septic death. In the study
by Perez et al (1994), 13 patients were treated with ifosfamide
(planned DI 0.7 g m–2 week–1), cisplatin (planned DI 50 mg m–2
week–1), and etoposide (planned DI 45 mg m–2 week–1) (dose level
–1) with severe leukopenia occurring in 62% of cases and severe
thrombocytopenia occurring in 38% of cases; the doses of ifos-
famide and etoposide could not be escalated as planned due to
severe myelotoxicity (neutropenic fever in two out of two patients
treated at dose level 0). In their phase II study, Fischer et al (1994),
treated two subsequent cohorts of patients with the ICE combina-
tion (ifosfamide 2 g m–2 day–1, days 1–3; cisplatin 25 mg m–2 day–1,
days 1–3; etoposide 120 mg m–2 day–1, days 1–3) administered
every 4 weeks or every 3 weeks with G-CSF support. In the 14
patients treated at 4-week intervals without G-CSF, a 57% of
severe neutropenia was reported, while in the 20 patients treated
every 3 weeks with G-CSF support severe neutropenia occurred in
65% of cases, with one episode of neutropenic fever. Interestingly,
there was a trend toward a higher response rate in patients
receiving intensified chemotherapy with G-CSF support. In the
present study, the use of prophylactic G-CSF administration
allowed the safe delivery of full doses of chemotherapy (median
delivered/planned DI ratio: one for all the three drugs) rarely
requiring dose reductions and/or delays. However, despite G-CSF
support we observed a relevant incidence of severe haematological
toxicity (Table 3), precluding further escalation of ifosfamide
doses as originally planned.
Our results with the ICE regimen confirm its high activity in
locally advanced patients, although caution should be exerted in
evaluating the response rate since the study design did not allow to
confirm responses at 4 weeks. The high systemic efficacy of this
regimen is also confirmed by the low incidence of non-cerebral
distant metastases (4/30 evaluable patients, 13%), with disease
progression mainly occurring locoregionally (19/30, 63%) and at
brain sites (7/30, 24%) (data not shown).
This observation raises the problem of the optimal strategy
for locoregional control in patients not amenable to surgery.
Sequential radiotherapy was employed in this study as locore-
gional treatment in the majority of patients achieving an objective
response or a SD after three cycles of chemotherapy, who did not
undergo surgery. Although the present study design does not allow
to draw firm conclusions about the role of radiotherapy as locore-
gional treatment after induction chemotherapy, in our subset of
patients chest irradiation caused a further reduction in tumour size,
with respect to that obtained after chemotherapy, in only 3/19
(16%) patients, while 8/19 patients (42%) experienced PD shortly
after the completion of radiotherapy (data not shown). These
results are in agreement with those recently reported from a
randomized study comparing further chemotherapy to loco-
regional irradiation in non-metastatic unresectable NSCLC
responding to initial chemotherapy (Sculier, 1998).
In stage IIIA-N2, several phase II studies have shown an overall
response rate ranging from 30 to 77%, with a pCR rate of 0–14%
and a median survival of 11–28 months. A high resection rate of up
to 87% has been reported in these studies, although the complete
resection rate, when reported, is somewhat lower. The design of
phase II studies does not allow to evaluate the benefit of preopera-
tive chemotherapy in terms of survival. Nevertheless, two recently
reported small phase III trials indicate that, even in the presence of
a limited activity of the induction regimen, survival is significantly
higher for chemotherapy-treated patients (Rosell et al, 1994;
Roth et al, 1994).
ICE combination in locally advanced NSCLC 1035
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Table 4 Non-haematological toxicity (maximum toxicity per patient, n = 39;
WHO)
G1 G2 G3 (%) G4 (%)
Nausea/vomiting 10 8 5 (13) –
Mucositis 6 2 – –
Renala 3– – –
Haematuria 3 – – –
Hepaticb 62 – –
Stipsis 4 1 – –
Diarrhoea – 1 – –
Neurotoxicity 8 – – –
Alopecia – – 39 (100) –
a Renal toxicity includes hyperazotaemia (two patients) and
hypercreatininaemia (one patient). Three additional patients had a transient
decrease in creatinine clearance (see Results). bHepatic toxicity includes
hypertransaminasaemia (G1: one patient; G2: one patient) and increase in
alkaline phosphatase levels (G1: five patients; G2: one patient).In the present study, a very small sample of ten stage IIIA
patients was included, all of whom were not suitable for surgical
resection at entry. In these patients the ICE combination allowed a
complete resection in eight out of ten patients; in addition, two out
of 33 stage IIIB patients could be completely resected after induc-
tion chemotherapy. A very interesting median disease-free and
overall survival of 26 months (range 1–54+) and 31 months (range
3–57+) respectively, was observed in this subgroup of radically
resected patients.
In conclusion, the ICE combination is an active regimen in
locally advanced NSCLC; with the use of G-CSF support, toxicity
was manageable even in out-patient setting. The interesting results
in stage IIIA patients warrant further explorations of this regimen
as induction chemotherapy in larger series.
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